29 Nov 2017 12:20
29 November 2017
Â
Â
Diurnal Group plc
("Diurnal" or the "Company")
Â
Directors' Dealings
Â
Â
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, received notification of the following Directors' share purchases on 27 November 2017:
Â
Martin Whitaker, Chief Executive Officer, purchased 3,703 Ordinary Shares at a price of 135 pence per Ordinary Share. Following the transaction Martin Whitaker has a total interest of 50,729 Ordinary Shares, representing 0.10% of the total voting rights.
Â
Richard Bungay, Chief Financial Officer, purchased 2,222 Ordinary Shares at a price of 135 pence per Ordinary Share. Following the transaction Richard Bungay has a total interest of 2,222 Ordinary Shares, representing 0.004% of the total voting rights.
Â
Richard Ross, Chief Scientific Officer, purchased 1,481 ordinary shares in the Company ("Ordinary Shares") at a price of 135 pence per Ordinary Share. Following the transaction Richard Ross has a total interest of 1,555,425 Ordinary Shares, representing 2.96% of the total voting rights.
Â
Â
For further information, please visit www.diurnal.co.uk or contact: | |
Diurnal Group plc | +44 (0)20 3727 1000 |
Martin Whitaker, CEO | |
Richard Bungay, CFO | |
Numis Securities Ltd (Nominated Adviser) | +44 (0)20 7260 1000 |
Nominated Adviser: Michael Meade, Paul Gillam, Freddie Barnfield | |
Corporate Broking: James Black | |
Panmure Gordon (UK) Limited (Joint Broker) | +44 (0) 20 7886 2500 |
Corporate Finance: Freddy Crossley / Duncan Monteith | |
Corporate Broking: Tom Salvesen | |
FTI Consulting | +44 (0)20 3727 1000 |
Simon Conway | |
Victoria Foster Mitchell | |
Notes to Editors
Â
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
Â
For further information about Diurnal, please visit www.diurnal.co.ukÂ
Â
Â
Â
Â
DEALING NOTIFICATION FORMFOR USE BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND THEIR CLOSELY ASSOCIATED PERSONS
Â
1. | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name: | Martin Whitaker | ||||
2. | Reason for the notification | |||||
a) | Position/status: | Chief Executive Officer | ||||
b) | Initial notification/Amendment: | Initial | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name: | Diurnal Group plc | ||||
b) | LEI: | 213800I2HNUNZN1LDH29 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary Shares of 5 pence each in Diurnal Group plc GB00BDB6Q760 | ||||
b) | Nature of the transaction: | Purchase | ||||
c) | Price(s) and volume(s): Â |
| ||||
d) | Aggregated information:  | Aggregated volume: 3,703 Price: £4999.05 | ||||
e) | Date of the transaction: | 27 November 2017 | ||||
f) | Place of the transaction: | XLON | ||||
Â
Â
Â
1. | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name: | Richard Bungay | ||||
2. | Reason for the notification | |||||
a) | Position/status: | Chief Financial Officer | ||||
b) | Initial notification/Amendment: | Initial | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name: | Diurnal Group plc | ||||
b) | LEI: | 213800I2HNUNZN1LDH29 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary Shares of 5 pence each in Diurnal Group plc GB00BDB6Q760 | ||||
b) | Nature of the transaction: | Purchase | ||||
c) | Price(s) and volume(s): Â |
| ||||
d) | Aggregated information:  | Aggregated volume: 2,222 Price: £2,999.70 | ||||
e) | Date of the transaction: | 27 November 2017 | ||||
f) | Place of the transaction: | XLON | ||||
Â
Â
Â
1. | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name: | Richard Ross | ||||
2. | Reason for the notification | |||||
a) | Position/status: | Chief Scientific Officer | ||||
b) | Initial notification/Amendment: | Initial | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name: | Diurnal Group plc | ||||
b) | LEI: | 213800I2HNUNZN1LDH29 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary Shares of 5 pence each in Diurnal Group plc GB00BDB6Q760 | ||||
b) | Nature of the transaction: | Purchase | ||||
c) | Price(s) and volume(s): Â |
| ||||
d) | Aggregated information:  | Aggregated volume: 1,481 Price: £1,999.35 | ||||
e) | Date of the transaction: | 27 November 2017 | ||||
f) | Place of the transaction: | XLON | ||||
Â
DNL.L (DNL)